Hematology | Topics

 
Convalescent Plasma Therapy Linked to Potential Survival Benefit for Patients With Hematologic Cancers and COVID-19
July 22, 2021

Patients with hematologic malignancies and COVID-19 may experience a survival benefit after receiving convalescent plasma therapy.

Ruxolitinib Improved Overall Response in the Treatment of Glucocorticoid-Refractory or -Dependent Chronic GVHD
July 21, 2021

Compared with a control therapy, ruxolitinib increased overall response and improved failure-free survival for patients with glucocorticoid-refractory or -dependent chronic graft-versus-host disease.

Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA
July 16, 2021

The ROCK-2–targeting agent belumosudil is now approved by the FDA to treat adult and pediatric patients with chronic graft-versus-host disease after 2 prior lines of therapy.